Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin for prevention of urinary kidney stone–forming parameters
IRCT20211203053261N2Phase 3Completed
- Sponsor
- Hamadan University of Medical Sciences
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial in Lithiasis comparing Empagliflozin with Placebo starch tablet (2 arms). Primary endpoints: 24-hour urine volume and 24-hour urine solutes. Started Jan 2023; status: completed.
02
Drugs
empagliflozin
03
Conditions
Lithiasis
Beyond the preview
Go deeper on IRCT20211203053261N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20211203053261N2.